Related Experiment Video
Updated: Jul 4, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy
Ping Ji1, Bharat Damle, Jingdong Xie
1Bristol-Myers Squibb Research and Development, Mail Stop E1215, Route 206 & Province Line Road, Princeton, NJ 08543, USA. pingji@bms.com
Abstract:
The effect of efavirenz on the pharmacokinetics of carbamazepine and vice versa was investigated in adult healthy subjects in a randomized, open-label, 2-period crossover, multiple-dose study. Subjects were randomized to receive either efavirenz 600 mg qd for 14 days or carbamazepine titrated to 400 mg qd for 21 days followed with both drugs for another 21 or 14 days. The pharmacokinetics was evaluated for efavirenz, carbamazepine, and the major metabolite of carbamazepine, carbamazepine-10,11-epoxide. Coadministration of carbamazepine with efavirenz significantly reduced the exposure of efavirenz (geometric mean ratios [90% confidence interval]: area of plasma concentration-time curve during the dosing interval of 24 hours [AUCtau], 0.64 [0.60-0.68]; maximum plasma concentration [C(max)], 0.79 [0.74, 0.85]) and carbamazepine (AUC(tau), 0.73 [0.67-0.80]; C(max), 0.80 [0.76, 0.85]) but had minimal impact on the exposure of carbamazepine-10,11-epoxide (AUC(tau), 0.99 [0.85-1.15]; C(max), 1.05 [0.91, 1.22]). In summary, a 2-way pharmacokinetic interaction between efavirenz and carbamazepine was demonstrated in this study.
Related Concept Videos
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Pharmacokinetics: Drug–Drug Interactions
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
Pharmacokinetics in Pediatric Patients: Drug Excretion
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Pharmacokinetic–Pharmacodynamic Relationship: Intensity of Dose-Effect Relationship
